Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.
We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.
We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.
Learn more about our Cardio Analysis Services
Experts in cardiac safety
Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
21
July 2023
Our research on behalf of Anylam Pharmaceuticals for a novel anti-hypertensive injectable, Zilbesiran, has been featured in the prestigious New England Journal of Medicine.
James Rickard appointed Chief Scientific Officer of Richmond Research Institute
13
June 2023
James Rickard is a Research Pharmacist and has been involved in translational research to deliver new therapeutic options to patients throughout his career. Driven by his desire for better outcomes for patients, he spent his early career working across several London Teaching Hospitals in Clinical Pharmacy, Drug Manufacture and Clinical Trials, culminating in taking up the role of Deputy Chief Pharmacist for Barts Health NHS Trust.
Here at Richmond Pharmacology, we focus mainly on Japanese cohorts in order to fast track global marketing authorisations in these important markets, ultimately reaching patients sooner.
Futureproofing early phase clinical research for the next generation of investigators.
20
March 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director
July 13, 2026
Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
